| Literature DB >> 35918671 |
Chunli Chen1,2,3, Yizhe Cheng1,2, Zhihan Zhang1,2, Xiang Zhang4, Jiakai Li4, Peiquan Zhao5, Xiaoyan Peng6,7,8.
Abstract
PURPOSE: To describe and analyze the clinical prognosis of infants diagnosed of familial exudative vitreoretinopathy (FEVR) with single gene mutation in long-term follow-up.Entities:
Keywords: Clinical features; FEVR; Gene; Prognosis; Relation between phenotypes and genotypes
Mesh:
Substances:
Year: 2022 PMID: 35918671 PMCID: PMC9347171 DOI: 10.1186/s12886-022-02522-8
Source DB: PubMed Journal: BMC Ophthalmol ISSN: 1471-2415 Impact factor: 2.086
Fig. 1Clinical statistics of FEVR patients. Patients with monocular involvement (MI), patients with binocular involvement and mild manifestation (Stage 1–3) in both sides (BM), patients with binocular involvement and severe (Stage 4–5) manifestation in both sides (BS), and patients with binocular involvement and mild manifestation in one eye and severe manifestation in the other eye (B[M + S])
Fig. 2The correlation between clinical phenotype and mutant genes. Patients with monocular involvement (MI), patients with binocular involvement and mild manifestation (Stage 1–3) in both sides (BM), patients with binocular involvement and severe (Stage 4–5) manifestation in both sides (BS), and patients with binocular involvement and mild manifestation in one eye and severe manifestation in the other eye [B(M + S)]
Clinical stages and severity in different single gene mutations
| Gene | Stage zero | Stage one | Stage two | Stage three | Stage four | Stage five | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eyes | Percentage | Eyes | Percentage | Eyes | Percentage | Eyes | Percentage | Eyes | Percentage | Eyes | Percentage | |
| LRP5 | 12 | 6.3% | 40 | 21.1% | 23 | 12.1% | 16 | 8.4% | 61 | 32.1% | 38 | 20.0% |
| FZD4 | 9 | 6.0% | 28 | 18.7% | 17 | 11.3% | 8 | 5.3% | 57 | 38.0% | 31 | 20.7% |
| KIF11 | 3 | 2.5% | 9 | 7.6% | 27 | 22.9% | 4 | 3.4% | 50 | 42.4% | 25 | 21.2% |
| NDP | 1 | 1.0% | 3 | 3.1% | 9 | 9.4% | 1 | 1.0% | 17 | 17.8% | 65 | 67.7% |
| TSPAN12 | 3 | 3.3% | 7 | 7.6% | 23 | 25.0% | 2 | 2.2% | 51 | 55.4% | 6 | 6.5% |
| ZNF408 | 4 | 16.7% | 1 | 4.2% | 9 | 37.5% | 2 | 8.3% | 5 | 20.8% | 3 | 12.5% |
Fig. 3The relation between the length of optic axis and gene
The axial length in patients with different genotypes and stages
| LRP5 | FZD4 | NDP | KIF11 | TSPAN12 | ZNF408 | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stage | Mean AL | SD | N | Mean AL | SD | N | Mean AL | SD | N | Mean AL | SD | N | Mean AL | SD | N | Mean AL | SD | N |
| I | 21.58 | 1.15 | 4 | 18.70 | 0.00 | 1 | - | - | - | - | - | - | - | - | - | - | - | - |
| II | 20.49 | 3.10 | 8 | 22.00 | 0.00 | 1 | 24.00 | 0.00 | 2 | 21.00 | 1.40 | 8 | 20.90 | 1.50 | 5 | 17.35 | 2.45 | 2 |
| III | 19.19 | 2.00 | 10 | 20.65 | 0.65 | 2 | - | - | - | 16.70 | 0.00 | 1 | - | - | - | 22.00 | 0.00 | 2 |
| IV | 19.00 | 2.29 | 43 | 19.99 | 3.76 | 27 | 19.51 | 1.12 | 8 | 17.82 | 1.58 | 22 | 19.25 | 3.03 | 22 | 18.70 | 0.00 | 1 |
| V | 14.74 | 2.28 | 28 | 16.09 | 4.89 | 20 | 16.10 | 2.09 | 28 | 16.36 | 0.83 | 12 | 19.10 | 3.40 | 4 | 17.97 | 2.93 | 3 |
AL Axial length, SD Standard deviation
The treatment of FEVR
| Gene | Closed-V | LSV | PPV + Silicone oil/C3F8 | SB | Cryotherapy | IVR | Laser coagulation | Strabotomy | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eyes | Percentage | Eyes | Percentage | Eyes | Percentage | Eyes | Percentage | Eyes | Percentage | Eyes | Percentage | Eyes | Percentage | Eyes | Percentage | |
| LRP5 ( | 22 | 11.6% | 6 | 3.2% | 9 | 4.7% | 2 | 1.1% | 1 | 0.5% | 15 | 7.9% | 17 | 8.9% | 1 | 0.5% |
| FZD4 ( | 20 | 13.3% | 3 | 2.0% | 6 | 4.0% | 0 | 0.0% | 0 | 0.0% | 3 | 2.0% | 11 | 7.3% | 0 | 0.0% |
| KIF11 ( | 19 | 16.1% | 0 | 0.0% | 3 | 2.5% | 2 | 1.7% | 0 | 0.0% | 3 | 2.5% | 2 | 1.7% | 2 | 1.7% |
| NDP ( | 30 | 31.3% | 4 | 4.2% | 2 | 2.1% | 0 | 0.0% | 0 | 0.0% | 14 | 14.6% | 5 | 5.2% | 0 | 0.0% |
| TSPAN12 ( | 6 | 6.5% | 1 | 1.1% | 1 | 1.1% | 0 | 0.0% | 1 | 1.1% | 6 | 6.5% | 4 | 4.3% | 1 | 1.1% |
| ZNF408 ( | 4 | 16.7% | 0 | 0.0% | 1 | 4.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 2 | 8.3% | 0 | 0.0% |
Closed-V Closed vitrectomy, LSV Lens-sparing vitrectomy, PPV Pars plana vitrectomy, SB Scleral buckling, IVR Intravitreal injection of ranibizumab
The relation between prognosis and gene
| Gene | Funnel-like unfold | Posterior pole unfold | Pupil closure | Secondary glaucoma | Corneal degeneration | Hyphema | Ocular atrophy | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eyes | Percentage | Eyes | Percentage | Eyes | Percentage | Eyes | Percentage | Eyes | Percentage | Eyes | Percentage | Eyes | Percentage | |
| LRP5 | 8 | 4.2% | 3 | 1.6% | 4 | 2.1% | 4 | 2.1% | 3 | 1.6% | 3 | 1.6% | 5 | 2.6% |
| FZD4 | 5 | 3.3% | 0 | 0.0% | 8 | 5.3% | 0 | 0.0% | 2 | 1.3% | 3 | 2.0% | 0 | 0.0% |
| KIF11 | 10 | 8.5% | 0 | 0.0% | 1 | 0.8% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| NDP | 10 | 10.4% | 0 | 0.0% | 15 | 15.6% | 0 | 0.0% | 6 | 6.3% | 3 | 3.1% | 8 | 8.3% |
| TSPAN12 | 3 | 3.3% | 0 | 0.0% | 0 | 0.0% | 1 | 1.1% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| ZNF408 | 2 | 8.3% | 0 | 0.0% | 2 | 8.3% | 2 | 8.3% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
Fig. 4Picture A showed corneal degeneration and valgus collar of pupil. Picture B showed secondary glaucoma, becoming bigger and proptosis of the eyeball, mild corneal edema and disappearance of anterior chamber. Picture C1 showed obvious increase of IOP and orbital-celluitis-like change. Picture C2 showed smaller size of the right eye after high IOP for 3 days. Picture D showed closure of pupil and disappearance. Picture E showed corneal edema, anterior chamber disappearing with hemorrhage. Picture F showed plenty of cholesterol crystallization in the anterior chamber. Picture G showed flat posterior pole after surgery. Picture H showed funnel-shaped unfold after surgery. Picture I showed atrophy of the eyeball